Last update Jan. 19, 2024

Anidulafungin

Compatible

Safe product and/or breastfeeding is the best option.

It is a semi-synthetic lipopeptide antifungal active against Aspergillus and Candida spp. It is used in the treatment of candidemia, esophageal candidiasis, and other forms of invasive candidiasis. intravenous administration.

IIts pharmacokinetic data (large volume of distribution, high molecular weight and high percentage of binding to plasma proteins) explain the minimal passage into breast milk, which is clinically irrelevant. (Eijsink 2024)

No side effects were found in an infant less than one month old of a mother treated with this drug. (Eijsink 2024)

Due to its protein nature, it is inactivated in the gastrointestinal tract, and is not absorbed, (it has virtually no oral bioavailability), which hinders or prevents its transfer from breastmilk to infant, except in premature babies and the immediate neonatal period, when there may be greater intestinal permeability.

Expert authors consider that it is not necessary to interrupt breastfeeding with this treatment (LactMed), which is probably compatible. (Hale)

Alternatives

  • Fluconazole (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Anidulafungin in other languages or writings:

  • أنيدولافونجين (Arabic)
  • Анидулафунгин (Cyrillic)
  • 阿尼芬净 (Chinese)
  • アニデュラフンギン (Japanese)
  • (4R,5R)-4,5-Dihydroxy-N2-{[4″-(pentyloxy)-p-terphenyl-4-yl]carbonyl}-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-l-threonyl-(3S,4S)-3-hydroxy-4-methyl-l-proline cyclic (6→1)-peptide; 1-((4R,5R)-4,5-Dihydroxy-N2-{[4″-(pentyloxy)(1,1′:4′,1″-terphenyl)-4-yl]carbonyl}-l-ornithine)-echinocandin B (Chemical name)
  • C58H73N7O17 (Molecular formula)
  • J02AX06 (ATC Code/s)

Group

Anidulafungin belongs to this group or family:

Tradenames

Main tradenames from several countries containing Anidulafungin in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. ≈ 0 %
Molecular weight 1.140 daltons
Protein Binding 84 - 99 %
VD 0.4 - 0.7 l/Kg
pKa 9.46 -
T½ 40 - 50 hours
Theoretical Dose 0.036 mg/Kg/d
Relative Dose 2.8 %
Ped.Relat.Dose 2.4 %

References

  1. LactMed. Drugs and Lactation Database (LactMed). Internet. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501922/ 2006 - Consulted on April 16, 2024 Full text (link to original source)
  2. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from https://www.halesmeds.com Consulted on April 10, 2024 Full text (link to original source)
  3. Eijsink JFH, Wieringa A, Vries-Koenjer MLM, Horst PGJT. Anidulafungin Levels in Breast Milk After Cessation of Treatment: A Case Report. Breastfeed Med. 2024 Jan 4. Consulted on Jan. 19, 2024 Abstract
  4. AEMPS. Anidulafungina. Ficha técnica 2022 Full text (in our servers)
  5. Pfizer. Anidulafungin. Drug Summary. 2014 Full text (in our servers)

Total visits

5,751

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche, España of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM